With 20 attorneys and over 200 staff, the national law firm of Aylstock, Witkin, Kreis & Overholtz is committed to protecting the rights of consumers who are seriously injured by defective products, drugs and medical devices. With over $2.5 Billion in settlements, our attorneys are nationally recognized as leaders in their field. Our attorneys have been recognized by the most preeminent legal organizations in the country.
Services
Justin G. Witkin received his B.S. in finance from Florida State University in 1992, and graduated with high honors from the University of Florida College of Law in 1995.
Mr. Kreis received his B.A. from Mercer University in Political Science attending under a four year academic/athletic scholarship and received a juris doctorate from Cumberland School of Law.
Mr. Overholtz has successfully handled thousands of defective drug and medical device cases, including fen-phen, Rezulin, Baycol, Bextra/Celebrex, Vioxx, Medtronic Defibrillators, and Guidant Defibrillators.
Mr. Kreis received his B.A. from Mercer University in Political Science attending under a four year academic/athletic scholarship and received a juris doctorate from Cumberland School of Law.
Mr. Overholtz has successfully handled thousands of defective drug and medical device cases, including fen-phen, Rezulin, Baycol, Bextra/Celebrex, Vioxx, Medtronic Defibrillators, and Guidant Defibrillators.
Aylstock, Witkin, Kreis & Overholtz is a Florida-based law firm geared towards protecting the rights of consumers who are seriously injured as a result of defective products, defective medical devices, accidents, or other negligent behavior.
On behalf of our clients, our firm has helped secure some of the largest verdicts and settlements ever awarded in the United States.
If you need help, let us put the expertise, technology, experience and resources that we have used to fight and win battles across the United States, to work for you.
On behalf of our clients, our firm has helped secure some of the largest verdicts and settlements ever awarded in the United States.
If you need help, let us put the expertise, technology, experience and resources that we have used to fight and win battles across the United States, to work for you.
The results of a recent clinical trial show that the diet drug Belviq (lorcaserin) is linked to an increased risk of developing cancer.
Drug manufacturer Eisai Inc. has "submitted a request to voluntarily withdraw the drug" according to Dr. Janet Woodcock, Director of the FDA's Center for Drug Evaluation and Research.
Now, "we're taking steps to notify the public, " she added, stating that "our review of the full clinical trial results shows that the potential risk of cancer associated with the drug outweighs the benefit of treatment."
Drug manufacturer Eisai Inc. has "submitted a request to voluntarily withdraw the drug" according to Dr. Janet Woodcock, Director of the FDA's Center for Drug Evaluation and Research.
Now, "we're taking steps to notify the public, " she added, stating that "our review of the full clinical trial results shows that the potential risk of cancer associated with the drug outweighs the benefit of treatment."
Nexium, Prilosec, and Prevacid, the leading sellers among drugs known as proton pump inhibitors (PPI's), have been found to increase the risk of developing kidney disease.
These popular drugs are taken for the treatment of heartburn, indigestion, gastritis and acid reflux with total sales exceeding thirteen billion dollars annually.
Aylstock, Witkin, Kreis & Overholtz Senior Partner Neil Overholtz recently appeared on the national program, The Ring of Fire, to discuss the injuries related to proton pump inhibitors.
These popular drugs are taken for the treatment of heartburn, indigestion, gastritis and acid reflux with total sales exceeding thirteen billion dollars annually.
Aylstock, Witkin, Kreis & Overholtz Senior Partner Neil Overholtz recently appeared on the national program, The Ring of Fire, to discuss the injuries related to proton pump inhibitors.
Zantac and other heartburn drugs based on the generic drug ranitidine have been found to contain the carcinogenic compound NDMA (N-nitrosodimethylamine).
This compound is classified as a potentially dangerous cancer-causing agent, and is used in gasoline, rocket fuel, as a stabilizer in industrial materials and as an additive to lubricants.
Zantac is sold by the maniufacturer Sanofi, as well as generically under the name ranitidine.
Lawsuits filed against the manufacturer maintain that Zantac contains levels of NDMA that are 26,000 times higher than the levels allowed by the FDA.
This compound is classified as a potentially dangerous cancer-causing agent, and is used in gasoline, rocket fuel, as a stabilizer in industrial materials and as an additive to lubricants.
Zantac is sold by the maniufacturer Sanofi, as well as generically under the name ranitidine.
Lawsuits filed against the manufacturer maintain that Zantac contains levels of NDMA that are 26,000 times higher than the levels allowed by the FDA.
Reviews
Be the first to review Aylstock Witkin Kreis & Overholtz.
Write a Review
